How a specific immune response can protect children's intestines from rotavirus infection
Official title: STING induced IFNL2/3 protects human intestinal epithelial cells from rotavirus infection
Funded at University of Florida · NIH-11104392 · Data updated 2026-11-12
This study is looking at how certain immune proteins can help protect kids under 11 from rotavirus, which causes serious diarrhea, and aims to find new ways to boost their immune response to fight this virus better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | June 6, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $502,248 |
| NIH project number | 1R01AI189780-01 |
| Project ID | NIH-11104392 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years who are at risk of rotavirus infection, especially those in developing countries.
✕Less likely to help
Patients who are older than 11 years or those who have already been vaccinated against rotavirus may not benefit from this research.
What this research studies
This research investigates how type III interferons, a group of immune signaling proteins, can help protect human intestinal cells from rotavirus infection, which is a leading cause of severe diarrhea and death in children worldwide. The study focuses on understanding the production and effectiveness of these interferons in response to rotavirus, particularly in children under 11 years old. By using genetic and pharmacological methods, researchers aim to uncover the specific roles of different types of interferons in combating this virus. The ultimate goal is to develop new therapeutic strategies that could enhance the immune response in vulnerable populations, especially in developing countries.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the impact of rotavirus infections in children, particularly in areas where current vaccines are less effective.
How similar studies have gone: Previous research has shown that type III interferons play a crucial role in antiviral responses, suggesting that this approach has potential for success.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Stanifer, Megan L — University of Florida
- Study coordinator: Stanifer, Megan L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.